Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
NCT04291703Phase 2Terminated
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Antithymocyte globulin (ATG) with Placebo (2 arms). Primary endpoint: Progression to Stage 3 Type 1 Diabetes at 13 months. Started Nov 2023; status: terminated.
02
Drugs
antithymocyte globulin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04291703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291703.